[{"address1": "6550 South Millrock Drive", "address2": "Suite G50", "city": "Salt Lake City", "state": "UT", "zip": "84121", "country": "United States", "phone": "801 676 9695", "website": "https://clene.com", "industry": "Packaged Foods", "industryKey": "packaged-foods", "industryDisp": "Packaged Foods", "sector": "Consumer Defensive", "sectorKey": "consumer-defensive", "sectorDisp": "Consumer Defensive", "longBusinessSummary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert  Etherington MBA", "age": 58, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 982088, "exercisedValue": 0, "unexercisedValue": 1333}, {"maxAge": 1, "name": "Mr. Morgan R. Brown CPA, M.B.A.", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 593204, "exercisedValue": 0, "unexercisedValue": 533}, {"maxAge": 1, "name": "Mr. Mark G. Mortenson ESQ.", "age": 67, "title": "Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 724057, "exercisedValue": 0, "unexercisedValue": 1333}, {"maxAge": 1, "name": "Mr. Jerry  Miraglia J.D.", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Anne Mcneil", "title": "Head of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael T. Hotchkin", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Benjamin M. Greenberg M.D., M.H.S.", "title": "Head of Medical", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.11, "open": 5.01, "dayLow": 5.01, "dayHigh": 5.4, "regularMarketPreviousClose": 5.11, "regularMarketOpen": 5.01, "regularMarketDayLow": 5.01, "regularMarketDayHigh": 5.4, "payoutRatio": 0.0, "beta": 0.874, "forwardPE": -2.4475, "volume": 109661, "regularMarketVolume": 109661, "averageVolume": 182714, "averageVolume10days": 140360, "averageDailyVolume10Day": 140360, "bid": 4.95, "ask": 5.15, "bidSize": 1, "askSize": 1, "marketCap": 59480456, "fiftyTwoWeekLow": 2.28, "fiftyTwoWeekHigh": 13.5, "allTimeHigh": 356.4, "allTimeLow": 2.28, "priceToSalesTrailing12Months": 277.94604, "fiftyDayAverage": 7.4166, "twoHundredDayAverage": 5.4721, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 65573600, "profitMargins": 0.0, "floatShares": 7452556, "sharesOutstanding": 11778307, "sharesShort": 516750, "sharesShortPriorMonth": 391393, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.05, "heldPercentInsiders": 0.28618, "heldPercentInstitutions": 0.17096001, "shortRatio": 1.74, "shortPercentOfFloat": 0.0753, "impliedSharesOutstanding": 11778308, "bookValue": -1.209, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -30496000, "trailingEps": -3.44, "forwardEps": -2.06333, "lastSplitFactor": "1:20", "lastSplitDate": 1720656000, "enterpriseToRevenue": 306.419, "enterpriseToEbitda": -2.888, "52WeekChange": 0.0645833, "SandP52WeekChange": 0.14799047, "quoteType": "EQUITY", "currentPrice": 5.05, "targetHighPrice": 48.0, "targetLowPrice": 23.0, "targetMeanPrice": 31.85714, "targetMedianPrice": 30.0, "recommendationMean": 1.14286, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 7925000, "totalCashPerShare": 0.767, "ebitda": -22703000, "totalDebt": 21312000, "quickRatio": 1.02, "currentRatio": 1.526, "totalRevenue": 214000, "revenuePerShare": 0.023, "returnOnAssets": -0.56243, "grossProfits": 176000, "freeCashflow": -13295375, "operatingCashflow": -18612000, "revenueGrowth": -0.828, "grossMargins": 0.82242996, "ebitdaMargins": 0.0, "operatingMargins": -376.53333, "financialCurrency": "USD", "symbol": "CLNN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Clene Inc.", "longName": "Clene Inc.", "earningsTimestampEnd": 1755088200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.44, "epsForward": -2.06333, "epsCurrentYear": -2.17333, "priceEpsCurrentYear": -2.3236232, "fiftyDayAverageChange": -2.3666, "fiftyDayAverageChangePercent": -0.319095, "twoHundredDayAverageChange": -0.4220996, "twoHundredDayAverageChangePercent": -0.07713667, "priceToBook": -4.177006, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Clene Nanomedicine Inc.", "nameChangeDate": "2026-01-16", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539869400000, "postMarketChangePercent": 2.003953, "postMarketPrice": 5.1512, "postMarketChange": 0.10119963, "regularMarketChange": -0.0599999, "regularMarketDayRange": "5.01 - 5.4", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 182714, "fiftyTwoWeekLowChange": 2.7700002, "fiftyTwoWeekLowChangePercent": 1.2149124, "fiftyTwoWeekRange": "2.28 - 13.5", "fiftyTwoWeekHighChange": -8.45, "fiftyTwoWeekHighChangePercent": -0.6259259, "fiftyTwoWeekChangePercent": 6.45833, "earningsTimestampStart": 1755088200, "gmtOffSetMilliseconds": -18000000, "esgPopulated": false, "regularMarketChangePercent": -1.17417, "regularMarketPrice": 5.05, "corporateActions": [], "postMarketTime": 1768603991, "regularMarketTime": 1768597200, "exchange": "NCM", "messageBoardId": "finmb_339429732", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "market": "us_market", "displayName": "Clene", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]